- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06854536
A Study on the Changes and Prognosis of Intestinal Microbiota and Function in Infants With Food Allergies
Study Overview
Status
Conditions
Detailed Description
Food allergy is a harmful immunological response to the ingestion of food proteins , causing various symptoms in multiple parts of the body, such as skin itching, redness, and hives; asthma and coughing in the respiratory tract; and nausea, vomiting, and diarrhea in the gastrointestinal tract. In severe cases, it can even lead to shock and death. FA primarily affects infants and young children, with a prevalence rate of up to 10% in developed countries. A epidemiological survey in China showed that the food allergy rate among children aged 0-36 months in eight cities was 6.53%, and the incidence rate has been increasing year by year. Currently, it is believed that FA in infancy is a risk factor for later eczema, allergic rhinitis, and asthma, which can severely impact children's growth and development and quality of life, increasing the burden on families and society. It has become a public health issue worldwide. Among infant food allergies, cow's milk and egg allergies are the most common. Cow's milk protein is the most commonly used protein source in ordinary infant formulas. Cow's milk protein allergy refers to an adverse reaction mediated by the immune mechanism caused by the body's response to cow's milk protein, which can be mediated by IgE, non-IgE, or both. Studies in some Chinese cities have shown that the prevalence of Cow's milk protein allergy among infants aged 0-3 years is approximately 0.83% to 3.5%. Since cow's milk protein is essential for infant growth and development, Cow's milk protein allergy can significantly affect children's growth and development and quality of life.
The pathogenesis of FA is not yet fully understood, but increasing evidence supports the involvement of abnormal gut microbiota in the pathophysiology of FA. Extensive basic research has found that certain probiotics play roles at multiple stages in the development of food allergies, including: In the intestinal lumen: regulating the structure of gut microbiota, increasing the production of secretory IgA, and modifying antigen peptides. At the intestinal mucosal level: improving intestinal mucosal permeability, stimulating the growth and differentiation of intestinal epithelial cells. At the submucosal level: regulating the function of the innate and adaptive immune systems, inducing oral tolerance, and affecting the function of the enteric neuroendocrine system. Studies have shown that bifidobacteria in the host gut can promote the development and maturation of the infant immune system, and their species composition and diversity have received significant attention regarding their impact on allergic diseases.
In summary, food allergies are relatively common in infancy and have been increasing annually. Therefore, this study aims to understand the changes in the gut microbiota and its metabolites in infants with food allergies, as well as the differences in gut microbiota between children with and without immune tolerance to food allergies, and to discover related gut microbial metabolites.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200025
- Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Children aged 1-36 months old
- Both men and women;
- The child's legal guardian signed the informed consent to participate in the study.
- The legal guardian of the child commits to follow the study procedures and cooperate with the entire study process
Exclusion Criteria:
- Probiotics or antibiotics within 1 month
- Associated with clinically significant abnormalities in liver and kidney function, nervous system, respiratory system, and coagulation function as determined by the investigator
- Unstable vital signs;
- Have other underlying medical conditions
- Individuals deemed unsuitable for this clinical trial.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Food-allergic children
Children diagnosed with food allergies
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intestinal microbiome analysis
Time Frame: The time point of confirming food allergy and the age of 36 months
|
The fecal samples from all participants will be collected and subjected to high-throughput metagenomic sequencing in order to elucidate the characteristics and composition of the intestinal microbiome in children with food allergies.
|
The time point of confirming food allergy and the age of 36 months
|
|
Intestinal microbiome metabolites analysis
Time Frame: The time point of confirming food allergy and the age of 36 months
|
This will be detected and analyzed by liquid chromatography-mass spectrometry (LC-MS) non-targeted metabolomics to analyze the metabolites of the intestinal microbiome.
|
The time point of confirming food allergy and the age of 36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Differences in clinical symptoms
Time Frame: 36 months of age
|
The incidence of ariway allergy in children with food allergy at the age of 36 months.
|
36 months of age
|
|
The percentile number of height of children at different groups
Time Frame: The time point of confirming food allergy and the age of 36 months
|
Compare the Percentile number of height of children with diagnosed with food allergy and healthy children.
|
The time point of confirming food allergy and the age of 36 months
|
|
The percentile number of head circumference of children at different group
Time Frame: The time point of confirming food allergy and the age of 36 months
|
Compare the Percentile number of head circumference of children with diagnosed with food allergy and healthy children.
|
The time point of confirming food allergy and the age of 36 months
|
|
The percentile number of weight of children at different groups
Time Frame: The time point of confirming food allergy and the age of 36 months
|
Compare the Percentile number of weight of children with diagnosed with food allergy and healthy children.
|
The time point of confirming food allergy and the age of 36 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GMSF-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.